A detailed history of Geode Capital Management, LLC transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 523,190 shares of TYRA stock, worth $7.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
523,190
Previous 522,674 0.1%
Holding current value
$7.32 Million
Previous $8.36 Million 47.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$16.7 - $24.36 $8,617 - $12,569
516 Added 0.1%
523,190 $12.3 Million
Q2 2024

Aug 09, 2024

BUY
$14.45 - $20.22 $1.53 Million - $2.14 Million
105,866 Added 25.4%
522,674 $8.36 Million
Q1 2024

May 13, 2024

BUY
$11.61 - $20.0 $967,565 - $1.67 Million
83,339 Added 24.99%
416,808 $6.84 Million
Q4 2023

Feb 13, 2024

BUY
$11.01 - $14.95 $209,090 - $283,915
18,991 Added 6.04%
333,469 $4.62 Million
Q3 2023

Nov 13, 2023

BUY
$13.15 - $16.08 $321,912 - $393,638
24,480 Added 8.44%
314,478 $4.33 Million
Q2 2023

Aug 11, 2023

BUY
$11.99 - $17.51 $46,689 - $68,183
3,894 Added 1.36%
289,998 $4.94 Million
Q1 2023

May 15, 2023

BUY
$6.85 - $16.22 $222,022 - $525,722
32,412 Added 12.78%
286,104 $4.6 Million
Q4 2022

Feb 13, 2023

BUY
$5.68 - $8.81 $35,454 - $54,992
6,242 Added 2.52%
253,692 $1.93 Million
Q3 2022

Nov 14, 2022

BUY
$6.61 - $12.42 $145,677 - $273,724
22,039 Added 9.78%
247,450 $2.18 Million
Q2 2022

Aug 12, 2022

BUY
$5.26 - $11.19 $78,174 - $166,305
14,862 Added 7.06%
225,411 $1.61 Million
Q1 2022

May 13, 2022

BUY
$10.03 - $14.09 $41,805 - $58,727
4,168 Added 2.02%
210,549 $2.25 Million
Q4 2021

Feb 11, 2022

BUY
$12.23 - $31.35 $2.52 Million - $6.47 Million
206,381 New
206,381 $2.9 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $588M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.